Cargando…

Tolvaptan for the Treatment of Refractory Ascites

Detalles Bibliográficos
Autores principales:	Kurosaki, Masayuki, Izumi, Namiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109554/ https://www.ncbi.nlm.nih.gov/pubmed/27746424

Ejemplares similares

Cases with Refractory Ascites and a Delayed Response to Tolvaptan
por: Hagiwara, Satoru, et al.
Publicado: (2016)

Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma
por: Imai, Michitaka, et al.
Publicado: (2020)

Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites
por: Arase, Yoshitaka, et al.
Publicado: (2018)

Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan
por: Iwasa, Motoh, et al.
Publicado: (2019)

Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites
por: Goto, Atsushi, et al.
Publicado: (2014)

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
por: Wang, Shuzhen, et al.
Publicado: (2018)

Impact of continued administration of tolvaptan on cirrhotic patients with ascites
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
por: Adachi, Takuya, et al.
Publicado: (2021)

First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan
por: Tsuruya, Kota, et al.
Publicado: (2023)

Long-Term Tolvaptan Treatment in Refractory Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2019)

Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio
por: Komiyama, Yasuyuki, et al.
Publicado: (2017)

Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites
por: Hosui, Atsushi, et al.
Publicado: (2021)

Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
por: Hirooka, Masashi, et al.
Publicado: (2022)

The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2017)

Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2021)

Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors
por: Izumi, Namiki, et al.
Publicado: (2010)

Ascites, refractory ascites and hyponatremia in cirrhosis
por: Fortune, Brett, et al.
Publicado: (2017)

Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia
por: Hayashi, Manabu, et al.
Publicado: (2018)

Therapy with the Combination of Tolvaptan and Furosemide for Refractory Edema in Nephrotic Syndrome
por: Meena, Jitendra, et al.
Publicado: (2020)

Beta-blocker therapy in refractory ascites: A steady march towards the truth
por: Bartell, Nicholas, et al.
Publicado: (2022)

Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites
por: Shigefuku, Ryuta, et al.
Publicado: (2021)

Refractory Chylous Ascites
por: Soto, Rodrigo, et al.
Publicado: (2008)

Management of refractory ascites
por: Wong, Florence
Publicado: (2023)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases
por: Tamaki, Nobuharu, et al.
Publicado: (2021)

Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study
por: Shiba, Shunsuke, et al.
Publicado: (2020)

Treatment of refractory ascites with an automated low‐flow ascites pump in patients with cirrhosis
por: Stirnimann, G., et al.
Publicado: (2017)

Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease
por: Mizuno, Hiroki, et al.
Publicado: (2017)

A new paradigm for the treatment of volume overload in heart failure-combined effect of tolvaptan with furosemide
por: Okamoto, Hiroshi
Publicado: (2013)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

Oncolytic adenovirus for treatment of malignant ascites
por: Hemminki, Akseli, et al.
Publicado: (2022)

Efficacy and safety of tolvaptan for refractory fluid collection and edema in the terminal cancer patients
por: Tsuzuki, Norimasa, et al.
Publicado: (2023)

Reinfusion of ascites during hemodialysis as a treatment of massive refractory ascites and acute renal failure
por: Hsu, Ta-Wei, et al.
Publicado: (2011)

Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study
por: Kudo, Toshihiro, et al.
Publicado: (2020)

Tolvaptan and its potential in the treatment of hyponatremia
por: Dixon, Megan B, et al.
Publicado: (2008)

Tolvaptan for the Treatment of Elephantiasis Nostras Verrucosa
por: Eda, Yuko, et al.
Publicado: (2019)

Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study)
por: Sakaida, Isao, et al.
Publicado: (2020)

Clinical Features of Refractory Ascites in Outpatients
por: Caly, Wanda Regina, et al.
Publicado: (2017)

Hereditary Hemorrhagic Telangiectasia and Refractory Ascites
por: Thandassery, Ragesh B., et al.
Publicado: (2020)

Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma
por: Miyazaki, Masayuki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hl9o3s4qpjo2su7mo5iithklct